Ginkgo Bioworks Holdings, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

DNA$12.37+9.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

20. Net Loss per Share

Net Loss per Share

The calculation of earnings per common share is as follows (in thousands, except share data):

	Year Ended December 31,
	2025	2024	2023
Numerator:
Net loss	$(312,763)	$(547,029)	$(892,869)
Denominator
Weighted average common shares outstanding	55,457,676	51,894,639	48,610,507
Net loss per share	$(5.64)	$(10.54)	$(18.37)

The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive:

	As of December 31,
	2025	2024	2023
Unvested PSUs	4,407,287	—	—
Warrants to purchase Class A common stock	1,295,622	1,295,622	1,295,622
Unvested RSUs	1,262,853	3,327,398	3,804,189
Earnout shares (1)	3,793,063	3,794,243	3,803,049
Outstanding stock options	366,567	767,520	192,208
Escrow shares (2)	—	20,332	—
	11,125,392	9,205,115	9,095,068

(1)Represents employee and non-employee earnout shares for which the service-based and/or market-based vesting conditions have not been satisfied.

(2)Represents restricted common stock issued in connection with asset acquisitions, held in escrow for indemnification purposes, and subject to forfeiture.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.